The announcement of an exclusive global arrangement with the Serum Institute of India for the supply of Bacillus Calmette-Guerin is a significant development for ImmunityBio. This partnership likely offers the company a competitive edge in its sector, potentially improving its market position and future revenue prospects. The positive stock price movement reflects investor optimism about the deal's impact on ImmunityBio's growth and profitability.